| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Batatasin III does not have a well-defined single molecular target. It is a natural product that has been studied for its potential in modulating cellular oxidative stress and signaling pathways relevant to cancer and neuroprotection. Its mechanism of action may involve modulation of cellular redox balance and signaling pathways.
|
|---|---|
| ln Vitro |
In H460 cells, batatasin III (25-100 μM; 48 h) has anti-proliferative action. Batatasin III is not harmful at values below 100 μM[1]. Batatasin III dramatically inhibits EMT, as seen by the up-regulation of E-cadherin and the decrease of Vimentin and N-cadherin[1].
Batatasin III has been studied for its in vitro activity in modulating cellular oxidative stress and signaling pathways. It shows germination inhibitory activity. In cell-based assays, Batatasin III may modulate oxidative stress markers and signaling pathways involved in cancer and neuroprotection. |
| ln Vivo |
Batatasin III has been studied for its potential in modulating cellular oxidative stress and signaling pathways relevant to cancer and neuroprotection. In vivo studies are needed to fully characterize its efficacy and safety profile in animal models.
|
| Enzyme Assay |
The in vitro assays for Batatasin III involve studying its effects on cellular oxidative stress and signaling pathways. Cells are treated with the compound, and markers of oxidative stress, cell viability, and signaling pathway activation are measured.
|
| Cell Assay |
The in vitro cell-based assay for Batatasin III involves treating cancer or neuronal cell lines with the compound and measuring its effects on cell viability, oxidative stress, and signaling pathways.
|
| Animal Protocol |
In vivo animal experiments for Batatasin III are not extensively documented.
|
| ADME/Pharmacokinetics |
Batatasin III has a molecular weight of 244.3 g/mol and a molecular formula of C15H16O3. It is a naturally occurring compound.
|
| Toxicity/Toxicokinetics |
As a research compound, its safety profile is evaluated in standard cytotoxicity assays. The compound is classified for research use only and is not intended for human therapeutic use.
|
| References | |
| Additional Infomation |
Batatasin III is a stilbene compound. Batatasin III has been reported in Coelogyne elata, Dendrobium draconis, and other organisms with available data.
Batatasin III (CAS 56684-87-8) is a naturally occurring bibenzyl compound. It has a molecular weight of 244.3 and a molecular formula of C15H16O3. It is being studied for its potential in cancer and neuroprotection research. It is not approved for clinical use and is available only for research purposes. |
| Molecular Formula |
C15H16O3
|
|---|---|
| Molecular Weight |
244.29
|
| Exact Mass |
258.126
|
| CAS # |
56684-87-8
|
| PubChem CID |
10466989
|
| Appearance |
White to off-white solid powder
|
| Density |
1.126g/cm3
|
| Boiling Point |
406.1ºC at 760 mmHg
|
| Melting Point |
93.5 - 94.5 °C
|
| Flash Point |
199.4ºC
|
| Index of Refraction |
1.572
|
| LogP |
3.194
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
18
|
| Complexity |
244
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC(=CC(=C1)O)CCC2=CC(=CC=C2)O
|
| InChi Key |
VYQXIUVIYICVCM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H16O3/c1-18-15-9-12(8-14(17)10-15)6-5-11-3-2-4-13(16)7-11/h2-4,7-10,16-17H,5-6H2,1H3
|
| Chemical Name |
3-[2-(3-hydroxyphenyl)ethyl]-5-methoxyphenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (409.35 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (10.23 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.23 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (10.23 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0935 mL | 20.4675 mL | 40.9350 mL | |
| 5 mM | 0.8187 mL | 4.0935 mL | 8.1870 mL | |
| 10 mM | 0.4093 mL | 2.0467 mL | 4.0935 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
